Use of oral cholera vaccine in complex emergencies: What next? Summary report of an expert meeting and recommendations of WHO

Journal of Health, Population and Nutrition

Volumn 25, Issue 2, 2007, Pages 244-261

  Chaignat, Claire Lise ^a   Monti, Victoria ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Cholera; Cholera vaccines; Complex emergencies; Evaluation studies

Indexed keywords

CHOLERA VACCINE;

CHOLERA; CONFERENCE PAPER; EMERGENCY; HUMAN; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; CHOLERA; CHOLERA VACCINES; EMERGENCIES; HUMANS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 35348978341     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Potential use of oral cholera vaccines in emergency situations: report of a meeting, Geneva, 12-13 May 1999. Geneva: World Health Organization, 1999:1-12. (CDS/CSR/EDC/99.4).
2. Cholera vaccines: a new public health tool? Report of a meeting, Geneva, 10-11 December 2002. Geneva: World Health Organization, 2004:1-23. (CDS/ CPE/ZFK/2004.5).
3. Oral cholera vaccine use in complex emergencies: what next? Report of a meeting, Cairo, Egypt, 14-16 December 2005. Geneva: World Health Organization, 2006:1-32. (WHO/CDS/NTD/IDM/2006.2). (http://www.who.int/ topics/cholera/publications/cholera_vaccines_emergencies_2005.pdf, accessed on 23 April 2007).
4. Cholera vaccines: a WHO position paper. Weekly Epidemiol Record 2001;76:117-24.
5. Jertborn M, Svennerholm AM, Holmgren J. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 1993;11:1007-12.
6. Viret JF, Dietrich G, Favre D. Biosafety aspects of recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 2004;22:2457-69.
7. Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Kaper JB et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect Dis 1992;166:837-41.
8. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wangsasaputra FF et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000;18:2399-410.
9. Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997;349:231-5.
10. Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 2002;80:2-8.
11. Thiem VD, Deen JL, von Seidlein L, Canh do G, Anh DD, Park JK et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 2006;24:4297-303.
12. Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 2005;192:573-9.
13. Garcia L, Jidy MD, Garcia H, Rodriquez BL, Fernandez R, Ano G et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005; 73:3018-24.
14. Girard MP, Steele D, Chaignat CL, Kieny MP. A review of vaccine research and development: human enteric infections. Vaccine 2006; 24:2732-50.
15. Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004;22:2444-51.
16. Glass RI, Steele AD. The value of cholera vaccines reassessed. Lancet 2005;366:7-9.
17. Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005;366:44-9.
18. Faruque SM, Chowdhury N, Kamruzzaman M, Dziejman M, Rahman MH, Sack DA et al. Genetic diversity and virulence potential of environmental Vibrio cholerae population in a cholera-endemic area. Proc Natl Acad Sci USA 2004;101:2123-8.
19. Use of the two-dose oral cholera vaccine in the context of a major natural disaster: report of a mass vaccination campaign in Aceh, Indonesia, 2005. Geneva: World Health Organization, 2006:S1-26. (CDS/NTD/ IDM/2006.1). (http://www.who.int/topics/cholera/publications/ final_tsunami.pdf, accessed on 30 April 2007).
20. Cavailler P, Lucas M, Perroud V, McChesney M, Ampuero S, Guerin PJ et al. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine 2006;24:4890-5.
21. Mozambique mass campaign tests the theory. Press Release 3, 14 January 2004. Geneva: World Health Organization, 2004. (http://www.who.int/ media-centre/news/releases/2004/pr3/en/ accessed on 30 April 2007).
22. Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005;352:757-67.
23. Sack DA. When should cholera vaccine be used in cholera-endemic areas? (editorial). J Health Popul Nutr 2003;21:299-303.